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Abstract
Clindamycin is commonly prescribed to treat children with skin and skin structure infections
(including those caused by community-acquired methicillin-resistant Staphylococcus aureus [CA-
MRSA]), yet little is known about the pharmacokinetics (PK) across pediatric age groups. A
population PK analysis was performed in NONMEM using samples collected in an opportunistic
study from children receiving intravenous clindamycin per standard of care. The final model was
used to optimize pediatric dosing to match adult exposure proven effective against CA-MRSA. A
total of 194 plasma PK samples collected from 125 children were included in the analysis. Median
age (range) was 3.3 years (0–20). Median dosing was 9.9 mg/kg/dose (3.8–15.1). A 1-
compartment model described the data well. The final model included body weight and a
sigmoidal maturation relationship between postmenstrual age (PMA) and clearance (CL): CL (L/
h)=13.7*(weight/70)0.75*(PMA3.1/(43.63.1+PMA3.1)); V (L)=61.8*(weight/70). Maturation
reached 50% adult CL values at ~44 weeks PMA. Our findings support age-based dosing.
Keywords
MRSA; population pharmacokinetics; clindamycin; pediatrics
Clindamycin is a lincosamide antibiotic commonly prescribed to treat children with skin and
skin structure infections (including those caused by community-acquired methicillin-
resistant Staphylococcus aureus [CA-MRSA]), pneumonia, osteomyelitis, and anaerobic
infections.1 Due to a rise in the incidence of CA-MRSA infections,2 the use of clindamycin
has increased significantly, and it is now the antibiotic most widely prescribed for this
indication in hospitalized pediatric patients.3
Following intravenous administration, clindamycin distributes extensively into tissues (with
the exception of cerebrospinal fluid) and, in healthy adults, has a volume of distribution at
steady state of 0.79 L/kg.4 Clindamycin is metabolized predominantly by cytochrome P450
(CYP) 3A4 to clindamycin sulfoxide and N-demethyl clindamycin.5 When measured in
vivo, metabolite concentrations, although quantifiable in bile and urine,6,7 are negligible in
plasma.8,9 In healthy adults, clindamycin’s clearance and half-life are ~0.3–0.4 L/h/kg and
2.1 hours, respectively.4,9 In spite of its widespread use, pharmacokinetic (PK) studies to
inform clindamycin dosing in children are limited. This is due in part to this drug being
marketed before studies were required in children, but also because of the many challenges
associated with conducting clinical trials in children, including low consent rates, limited
access to the population of interest, and the frequent need for research blood draws to obtain
PK samples.
To overcome these latter challenges, opportunistic study designs capitalizing on standard
medical care procedures have been implemented successfully in children.10–12 In this study
design, patients prescribed a drug of interest by the treating physician are identified and
consented for PK sample collection, optimally, at the time of routine laboratory draws.13 By
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not administering a drug solely for research purposes and timing blood draws with standard-
of-care procedures, there is minimal study-related risk to the patient, and higher consent
rates are obtained. However, opportunistic study designs have not been broadly
implemented in children because of a lack of consistently successful applications
demonstrating their value.11,12
Clindamycin is an off-patent, widely used, yet understudied pediatric therapeutic, the dosing
for which could be informed by such an efficient and cost-effective opportunistic design.
Furthermore, given the biotransformation pathway involved, it is likely that important
developmental changes during childhood will affect clindamycin drug disposition, and the
PK data collected will inform pediatric dosing across age groups. An opportunistic study
design facilitates collection of PK data across the pediatric age continuum, allowing for
differences in clindamycin elimination and distribution to be assessed. A final rationale for
reassessing clindamycin PK is that historical studies in children used bioassays incapable of
separating clindamycin from its bioactive metabolites, perhaps over-estimating clindamycin
exposure in children.14,15
The objectives of this study were to characterize clindamycin drug disposition across the age
continuum from premature infants to adolescents using an opportunistic clinical trial design
and to optimize clindamycin dosing in this population.
RESULTS
Patient characteristics
A total of 194 plasma PK samples collected from 125 subjects receiving intravenous
clindamycin were included in the analysis; 2 additional samples below the limit of
quantification were excluded. Sixty five percent of samples (127/194) were collected for
research purposes. The five most common indications for clindamycin administration were
Staphylococcus and skin and skin structure infections (N=41/125), prophylaxis (21/125),
other infections (21/125), intra-abdominal infection (10/125), and pneumonia (7/125). The
median (range) number of samples per subject, dose, and daily dosage were 1 sample (1–6),
9.9 mg/kg/dose (3.8–15.1), and 29.7 mg/kg/day (7.6–52.2), respectively. Patient
demographic variables are summarized in Table 1. The median (range) postnatal age (PNA)
and weight were 3.3 years (1 day–20 years) and 17.3 kg (0.5–139.8), respectively. Fifty six
percent (70/125) of subjects were male; 76% (95/125) were white. Twenty five percent of
subjects (31/125) were obese (body mass index ≥ 95th percentile). A total of 35 subjects
were ≤120 days of PNA; of these 57% (20/35) were ≤32 weeks gestational age (GA) at birth
and were studied at median (range) 9.5 days PNA (2–61) and 28.8 weeks postmenstrual age
(PMA) (23.6–37.6).
Population PK model development and evaluation
Clindamycin plasma concentrations versus time data are shown in Figure 1. A 1-
compartment body model described the data well. Scaling of clearance (CL) and volume of
distribution (V) parameters by weight using a fixed exponent allometric relationship
(CL=0.75; V=1) resulted in a 341-point reduction in the -2 log likelihood objective function
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value (OFV). As a result, additional covariate relationships were evaluated after adjusting
for size-based differences using total body weight. A sigmoidal EMAX maturation function
accounting for PMA-based differences in drug CL resulted in a 66-point further reduction in
the OFV and reduced the between-subject variability by 25.4% (Supplemental Table 1).
When compared with a sigmoidal relationship, linear and power maturation functions using
PMA and PNA had lesser reductions in the OFV. After accounting for size- and age-based
differences in PK parameters, no other covariates (including obesity on V) reached statistical
significance.
The final population PK (PPK) model included body weight and a sigmoidal EMAX
maturation relationship between PMA and CL (Table 2):
Maturation reached 50% adult CL (TM50) values at approximately 44 weeks PMA.
Between-subject variability in CL was 57.1%. Between-subject random effect (η) shrinkage
for CL was 9%, while epsilon (ε) shrinkage was 20.8%. Estimation of between-subject
variability in V was not supported by the data; a high η-shrinkage (49%) was observed for
this parameter. A proportional residual error model characterized unexplained residual
variability well and was estimated at 39.5%. There were no obvious trends or model
misspecification identified in the diagnostic plots for the final model (Figure 2). The visual
predictive check (VPC) indicated that the final model described the observed data
adequately; 11% of the observed concentrations fell outside the 90% simulated prediction
interval (Supplemental Figure 1). Median bootstrap estimates were within approximately 3%
of final model estimates.
Individual empirical Bayesian estimates were compared across age groups (Table 3). As
described using the sigmoidal maturation function, CL increases from 2.8 L/h/70 kg at 28
weeks PMA to an adult value of 13.7 L/h/70 kg (Figure 3). A notable difference in median
(range) weight-normalized CL was observed between infants ≤32 weeks PMA (0.11 L/h/kg
[0.06–0.31]), >32–40 weeks PMA (0.16 L/h/kg [0.06–0.26]), and >40–60 weeks PMA (0.29
L/h/kg [0.08–0.75]). Because between-subject variability in V was not incorporated into the
model, individual estimates of V did not vary across age groups.
Dose-exposure relationship
Dosing simulations were performed using the final PPK model. A virtual adult patient (70
kg weight) administered clindamycin 600 mg intravenously every 8 hours had a median
(2.5th, 97.5th percentiles) area under the concentration versus time curve from 0–8 hours at
steady state (AUCss,0–8) of 42.9 (14.2, 132) mcg*h/mL. Optimized PMA-based dosing
resulted in simulated median AUCss,0–8 comparable to the virtual adult estimate
(administered every 8 hours): 42.9 mcg*h/mL (5 mg/kg, PMA ≤32 weeks); 42.1 mcg*h/mL
(7 mg/kg, PMA >32–40 weeks); 42.7 mcg*h/mL (9 mg/kg, PMA >40–60 weeks) (Figure 4).
For older infants (≥5 months PNA) to adolescents, age-based dosing resulted in a median
AUCss,0–8 similar to the adult prediction (administered every 8 hours): 42.2 mcg*h/mL (≥5
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months–6 years, 12 mg/kg); 46.9 mcg*h/mL (>6–18 years, 10 mg/kg) (Figure 5). Median
simulated maximal drug concentrations at steady state (Css,max) were also comparable to the
predicted level for adults (within 25%) for all age groups except for PMA >28–32 weeks
(~30% lower) (Supplemental Tables 2 and 3).
DISCUSSION
Clindamycin is prescribed frequently to children with common infections. Despite its
widespread use, limited PK studies have been performed to characterize clindamycin
disposition in the pediatric (i.e., neonatal to adolescent) population. Similar to a published
clindamycin PPK model for adults,16 a 1-compartment model described the pediatric data
well, and population estimates for CL and V, standardized to a 70 kg adult (13.7 L/h and
61.8 L, respectively), were comparable to values previously reported for adults (15.2 L/h
and 66.2 L).16
After accounting for size-based (i.e., body weight) differences in PK parameters using a
fixed exponent allometric relationship (CL=0.75; V=1), a sigmoidal EMAX maturation
model successfully characterized developmental changes in CL across the age continuum
from preterm infants to adolescents. This finding is consistent with prior evaluations of drug
disposition in children, including dexmedetomidine, lamivudine, and vancomycin.17–19 The
maturation half-life and slope factor for the maturation function were 43.5 weeks and 3.1,
respectively. These estimates are similar to values reported previously for other CYP3A
substrates: 39.7 weeks and 1 (slope factor not estimated) for lopinavir20 and 35.7 weeks and
3.87 for levobupivacaine.21,22
The estimate of maturation half-life observed in this study also agrees with available data
describing the ontogeny of CYP3A expression in the human liver.23–25 Following birth,
CYP3A7, the predominant isoform in the fetal liver, is known to decrease with PNA, though
significant expression has been noted up to 6 months PNA.25 In contrast, CYP3A4
expression is low at birth, and functional enzymatic activity is rapidly acquired.23–25 One
analysis pooled available hepatic CYP3A expression data and estimated a maturation half-
life of 0.31 years (~16 weeks PNA).26 Given that the median GA was 31.1 weeks in our
study, a maturation half-life of 47 weeks (PMA) corresponds well with the estimate
observed in our PPK analysis.
Maturation in drug CL as a function of age is reflected in individual parameter estimates
observed in this study. In infants, prematurity had a significant impact on CL; when
stratified based on GA (≤32 weeks vs. >32 weeks), a notably lower CL was observed for
infants ≤32 weeks. However, CL estimates are at least 2-fold higher than those published
previously for infants, perhaps due to an older PNA in our cohort. One study that evaluated
clindamycin PK following intravenous administration (17.9–44 mg/kg/day) in 12 newborn
infants (GA 26–39 weeks; PNA 1–24 days; weight 0.8–2.6 kg) reported a mean (range) CL
of 0.06 (0.02–0.13) L/h/kg.15 In a separate study of 40 infants (GA 28–40 weeks; PNA 2–27
days; weight 1–9.6 kg) who received intravenous clindamycin (15–20 mg/kg/day), CL was
significantly higher in infants >4 weeks age (1.59 L/h) when compared with premature (0.29
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L/h) or term (0.68 L/h) infants at birth (body weights were not reported for each respective
age group).
Dosing simulations showed that the median simulated AUCss,0–8 following a 600 mg dose
in a 70 kg adult was comparable to previously published values for adults.27 Simulations
support age-based dosing (all regimens every 8 hours) with the lowest weight-normalized
dose administered to premature infants ≤32 weeks PMA. Higher doses for infants 32–40
weeks and 40–60 weeks PMA are supported by a greater than 30% and 100% higher
(relative to premature infants <32 weeks PMA) weight-normalized clearance, respectively.
Older infants and children (>5 months–18 years) require higher weight-normalized doses
relative to adults to match adult exposure. This finding is consistent with allometric scaling
of CL across the spectrum of age using body weight.28
The clindamycin adult dose selected to match pediatric exposure was 600 mg every 8 hours,
as is recommended in clinical practice guidelines for CA-MRSA infections.1 This dose has
been shown to be bactericidal both in vitro and in a murine thigh infection model for up to
72 hours against a CA-MRSA strain lacking inducible clindamycin resistance.29 In children,
current treatment guidelines recommend use of clindamycin 10–13 mg/kg/dose every 6–8
hours (not to exceed 40 mg/kg/day) for skin and soft tissue infections, pneumonia, and
osteomyelitis, if clindamycin resistance rate is low (<10%) and CA-MRSA is the likely
pathogen.1 Clinical studies evaluating clindamycin use for osteomyelitis and invasive
infections caused by CA-MRSA have described use of clindamycin intravenous doses of
20–40 mg/kg/day in the pediatric population.30–32
In one study, 48 pediatric patients, age 1 month to 14 years, received 20–30 mg/kg/day of
clindamycin (administered in 3 divided doses) for treatment of osteomyelitis and septic
arthritis. Serum clindamycin concentrations were 8- to 32-fold higher than the minimum
inhibitory concentration (MIC) of organisms isolated, bone and synovial fluid
concentrations were 60–85% those reported in serum, and a favorable response was
observed in 88% (42/48) of children (delayed response in 5 patients).30 Similarly, another
study described use of clindamycin (30 mg/kg/day in 3 divided doses) in children (mean ±
SD age, 6.3 ± 4 years) for treatment of osteomyelitis due to S. aureus, and 92% (11/12) of
children had a favorable response to treatment.31 For treatment of bacteremia and
complicated pneumonia, a retrospective study described effective use of clindamycin 40
mg/kg/day in children.32 Doses up to 50 mg/kg/day have been studied in pediatric patients
(5 weeks to 15 years age) with osteomyelitis.33 A favorable safety profile for clindamycin
was observed across all studies.
Use of an opportunistic study design was an efficient approach that resulted in development
of a PPK model that characterizes clindamycin drug disposition in children. The model was
then used to assess optimal dosing for treatment of CA-MRSA infections in children.
However, study limitations include: 1) the timing and number of samples varied
significantly across patients, which may have prevented precise estimation of the between-
subject variability in V and determination of the influence of obesity on PK parameter
estimates; 2) despite accounting for a size and age effect on CL, between-subject variability
was 57%, suggesting that additional sources of variability need to be characterized; 3)
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protein binding was not assessed, potentially limiting our ability to characterize differences
in unbound drug concentrations in infants versus older populations; and 4) laboratory values
(e.g., serum creatinine) were not available for the majority of patients enrolled in this study
and may have limited our ability to evaluate the influence of these covariates on PK
parameter estimates. For adults, however, product labeling does not recommend dosage
adjustments in the presence of mild or moderate renal or hepatic impairment, and it is




PK samples used to develop the PPK model were collected from the Pharmacokinetics of
Understudied Drugs Administered to Children per Standard of Care (POPS) trial
(clinicaltrials.gov #NCT01431326; protocol NICHD-2011-POP01), a multi-center (N=24),
prospective, PK and safety study in children (<21 years of age). Children who received one
of the targeted drugs of interest (including clindamycin) per standard of care as administered
by their treating caregiver were eligible for enrollment. Exclusion criteria included failure to
obtain consent/assent or known pregnancy. PK samples were collected either at the time of
clinical laboratory collections, or if the parent/patient consented, following a specific
collection for study purposes. Because this was a standard-of-care study, dosing and PK
sample collection times varied between subjects. Standard-of-care laboratory assessments
(e.g., comprehensive metabolic panel) were recorded if collected within 24 hours of a study
dose of the drug. GA and PNA were collected in infants ≤120 days PNA. For infants >120
days of age, a GA of 40 weeks was assumed. Subjects were enrolled in the study for up to
90 days. Each study protocol was reviewed and approved by the institutional review board
of each participating institution.
Drug dosing and sample collection
Dosing information was collected for up to 8 doses prior to the sampling dose (last dose
prior to plasma PK sample collection). PK samples were collected at the time of routine
laboratory (i.e., standard-of-care) blood draws unless the parent/guardian of the participating
child provided consent allowing for sample collection to be performed for research purposes
(specifically for the study). In the latter case, PK blood collections were obtained without
regard to alignment with timing of routine laboratory blood draws. The guidelines for PK
sampling time points were designed according to the frequency of administration of the
study drug (Supplemental Table 4). The same sample processing and storage procedures
were followed for all PK samples (collected with standard-of-care blood draws and those
collected for research purposes). A maximum of 10 blood samples were collected per study
participant.
Analytical methods
Whole blood was collected (200 μL) in an EDTA-K2 microtainer and was processed
immediately prior to freezing at the study sites. PK samples were sent to the Pediatric Trials
Network central laboratory (OpAns, LLC, Durham, NC) for storage and analysis.
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Clindamycin concentrations were quantified using a validated liquid chromatography-
tandem spectrometry (LC-MS/MS) assay (assay did not quantify metabolite concentrations).
The chromatography system and mass spectrometer used for sample analysis were the
Agilent 1200 series high-performance liquid chromatography (HPLC) and an Agilent 6400
series triple quadrupole system, respectively. The Pursuit XRS Ultra C18 column (50 mm
length x 2 mm internal diameter, 2.8 μm particle size, Agilent) and a gradient mobile phase
(water containing 0.5% (v/v) formic acid; methanol containing 0.1% (v/v) formic acid) were
used. The validation range for the assay was 50–50,000 ng/mL. The lower limit of
quantification was 50 ng/mL. Accuracy and precision were within the FDA bioanalytical
assay validation criteria (e.g., ±15%).
Structural model development
Clindamycin plasma PK data collected following intravenous administration were analyzed
with a nonlinear mixed effects modeling approach using the software NONMEM (version
7.2, Icon Solutions, Ellicott City, MD). The first-order conditional estimation method with
interaction (FOCE-I) was used for all model runs. Run management was performed using
Pirana (version 2.8.1).35 Visual predictive checks and bootstrap methods were performed
with Perl-speaks-NONMEM (PsN, version 3.6.2).36 Data manipulation and visualization
were performed using R (version 3.0.2, R Foundation for Statistical Computing, Vienna,
Austria) and RStudio (version 0.97.551, RStudio, Boston, MA), with the packages lattice,
Xpose and ggplot2 used for the latter.37–39
Based on visual inspection of the PK data and a review of the primary literature, 1- and 2-
compartment PK models were evaluated using the ADVAN1 TRANS2 and ADVAN3
TRANS4 subroutines, respectively, in NONMEM. Between-subject variability was assessed
for PK model parameters using an exponential relationship (Equation 1).
(1)
Where Pij denotes the estimate of parameter j in the ith individual; θPop,j is the population
value for parameter j; and ηij denotes the deviation from the average population value for
parameter j in the ith individual. The random variable η is assumed to be normally
distributed with a mean zero and variance ω2. The covariances between η parameters (e.g.,
CL and V) were estimated. Proportional, additive, and combined (proportional plus additive)
residual error models were evaluated.
Covariate analysis
The potential effects of clinical covariates on PK parameters were evaluated if a relationship
was suggested by visual inspection of scatter and box plots (continuous and categorical
variables, respectively) of the individual deviations from the population-typical value for PK
parameters (ETAs) against covariates. The following covariates were explored: PNA, PMA,
GA (≤32 weeks vs. >32 weeks), aspartate aminotransferase, alanine aminotransferase, serum
creatinine, bilirubin (total [TBIL] and direct [DBIL]), serum albumin, obese status (body
mass index ≥95th percentile), ethnicity, and sex. PMA is defined as the sum of the GA
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(weeks) plus PNA in weeks (days/7). A 32-week GA cutoff was selected to evaluate the
impact of prematurity on drug disposition.40
Body weight (WT) was assumed to be a significant covariate for CL and V and was
included in the base model prior to assessment of other covariates. The relationship between
WT and PK parameters was characterized using a fixed exponent allometric relationship for
CL parameters and a linear-scale for V parameters (Equations 2 and 3).21 Scaling was based
on a 70 kg standardized adult weight as shown below.
(2)
(3)
Where CLstd and Vstd represent population estimates of CL and V in a 70 kg subject and WTi
denotes body weight for the ith subject.
With the exception of WT and age, continuous covariates were normalized to the population
median value as described in Equation 4, whereas for categorical covariates such as obese
status, a relationship as shown in Equation 5 was used.
(4)
(5)
Where covi denotes the individual covariate value; covm is the population median covariate
value; θcov is a parameter which represents the covariate effect; and OBESE is a categorical
variable which takes on a value of unity when obese and zero when non-obese or in cases
where obese status was not assessed (<2 years age) or unavailable.
The relationship between age (e.g., PMA, PNA) and CL was explored using a sigmoidal
EMAX maturation function as shown in Equation 6.41
(6)
Where FPMA denotes the fraction of the adult CL value; TM50 represents the value of PMA
(weeks) when 50% adult clearance is reached; and HILL is a slope parameter for the
sigmoidal maturation model. Power and linear functions using PMA and PNA were also
evaluated.
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A forward inclusion (p<0.05 and ΔOFV > 3.8) and backward elimination (p<0.001 and
ΔOFV >10.8) approach was used to assess the statistical significance of relevant covariates.
Missing covariate values were imputed using the median value for the sample.
Model evaluation
During the PPK model-building process, successful minimization, diagnostic plots,
plausibility and precision of parameter estimates, as well as objective function and shrinkage
values, were used to assess model appropriateness.42 Diagnostic plots generated included:
individual predictions (IPRED) and population predictions (PRED) vs. observations;
conditional weighted residuals (CWRES) vs. PRED and time; and individual weighted
residuals (IWRES) vs. IPRED.
Parameter precision for the final PPK was evaluated using non-parametric bootstrapping
(1000 replicates) to generate 95% confidence intervals (CI) for parameter estimates using
the percentile method. Visual predictive checks were performed whereby the base and final
models were used to generate 1000 Monte Carlo simulation replicates per time point of
clindamycin exposure, and simulated results were compared with those observed in the
study. The dosing and covariate values used to generate the simulations in the visual
predictive checks were the same as those used in the study population.
Dose-exposure relationship
Clindamycin has a prolonged post-antibiotic effect, and AUC is an important predictor of
drug efficacy.43 Pediatric dosing regimens were optimized to match (within 20%) median
adult (70 kg WT) clindamycin exposure, specifically AUCss,0–8, following intravenous
administration of 600 mg every 8 hours—the dose recommended for CA-MRSA
pneumonia, osteomyelitis, and skin and soft tissue infections in adults.1 Css,max and
minimum steady-state concentrations (Css,min) were also computed using the intermittent
infusion equation.
Covariate values used in the simulations were the same as those in the study population used
for model development. Using PK parameter estimates from the final population model,
1000 concentrations versus time profiles were simulated for each virtual patient. A
maximum absolute dose of 900 mg every 8 hours and infusion duration of 0.5 hours was
used in all dosing simulations.
CONCLUSION
A PPK model was developed with data collected from premature infants to adolescents
using an opportunistic study design. A 1-compartment model, accounting for size-based
differences with body weight and maturational factors and using a sigmoidal function,
characterized drug disposition across pediatric age groups. The final model was applied to
simulate drug exposure. Age-based dosing is recommended to match dosing recommended
in adults.
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What is the current knowledge on the topic?
Limited published data suggest that there are important age-dependent differences in
clindamycin disposition between children and adults.
What question does this study address?
This study sought to characterize clindamycin drug disposition across the age continuum
from premature infants to adolescents using an opportunistic clinical trial design and to
optimize dosing against CA-MRSA infections in this population.
What does this study adds to our knowledge?
Based on Monte Carlo simulations, age-based dosing, which matches adult exposure
proven effective against CA-MRSA, is recommended: PMA≤32 weeks, 5 mg/kg; PMA
>32–40 weeks, 7 mg/kg; PMA >40–60 weeks, 9 mg/kg; 5 months – 6 years, 12 mg/kg;
>6 – 18 years of age, 10 mg/kg.
How this might change clinical pharmacology and therapeutics?
This study showed that an opportunistic study design can be used to efficiently
characterize drug disposition for an off-patent therapeutic in the pediatric population and
can serve as an example for future investigations.
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Clindamycin concentration versus time curve. The solid black line represents the loess
curve.
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Diagnostic plots for the final model. CWRES, conditional weighted residuals.
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Clearance as a function of postmenstrual age. Individual clearance values for subjects with
PMA≤200 weeks (~3 years age). The solid black line denotes the sigmoidal maturation
function included in the final model.
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Optimized clindamycin dosing for infants of postmenstrual age ≤60 weeks (~5 months age).
AUC, area under the curve at steady-state.
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Optimized clindamycin dosing for infants (>5 months postnatal age) to adolescents. AUC,
area under the curve at steady-state.
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